Preclinical Development Definition & Meaning | Health Care Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Preclinical Development

Health Care Term

Preclinical development in the healthcare industry is the early stage of drug development that takes place before clinical trials. It involves the discovery and development of new drugs, and the evaluation of their safety and effectiveness in animal models.

The preclinical stage is critical to drug development as it provides important information and results needed to ensure that a new drug is safe, effective, and suitable for human use. This stage encompasses several activities, including drug discovery, characterization, optimization, and formulation. It also involves the study of a drug*s pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics (how the drug affects the body).

This stage of drug development is typically carried out in academic and industry research facilities, where scientists use various techniques and methods to test potential drug candidates. These tests involve evaluating the toxicity, pharmacological activity, and pharmacokinetics of the drugs in animals. Once preclinical testing is complete, the drug is submitted to regulatory authorities for review and approval to proceed to clinical trials.

In summary, preclinical development plays a crucial role in the healthcare industry, as it is necessary to establish the safety, efficacy, and quality of new drugs before they can be tested in humans. Through preclinical development, healthcare organizations can ensure that the drugs they develop are safe and effective for use in treating various diseases and conditions.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P